Use of bevacizumab as a first-line treatment for metastatic breast cancer.
about
The best of both worlds - managing the cancer, saving the bone.Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials.Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.Toxic elements as biomarkers for breast cancer: a meta-analysis study.Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.
P2860
Use of bevacizumab as a first-line treatment for metastatic breast cancer.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Use of bevacizumab as a first-line treatment for metastatic breast cancer.
@ast
Use of bevacizumab as a first-line treatment for metastatic breast cancer.
@en
type
label
Use of bevacizumab as a first-line treatment for metastatic breast cancer.
@ast
Use of bevacizumab as a first-line treatment for metastatic breast cancer.
@en
prefLabel
Use of bevacizumab as a first-line treatment for metastatic breast cancer.
@ast
Use of bevacizumab as a first-line treatment for metastatic breast cancer.
@en
P2093
P2860
P356
P1433
P1476
Use of bevacizumab as a first-line treatment for metastatic breast cancer.
@en
P2093
A Arcediano
A I Ballesteros
E López-Miranda
P2860
P304
P356
10.3747/CO.22.2210
P577
2015-04-01T00:00:00Z